首頁 > 市場調查報告書 > 製藥

疫苗

市場調查報告書

商品編碼

1572430

獸用狂犬病疫苗市場、機會、成長動力、產業趨勢分析與預測，2024-2032

Veterinary Rabies Vaccines Market, Opportunity, Growth Drivers, Industry Trend Analysis and Forecast, 2024-2032

出版日期: 2024年08月16日 | 出版商:

Global Market Insights Inc. | 英文 219 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

2023 年，全球獸用狂犬病疫苗市場價值為5.025 億美元，預計2024 年至2032 年複合年成長率為4.2%，原因是動物狂犬病患病率不斷上升，以及人們對其人畜共患病影響的認知不斷增強。

全球寵物擁有量的激增進一步推動了市場的發展，因為主人越來越認知到為寵物接種狂犬病疫苗的重要性。發展中國家的都市化和畜牧業的成長也推動了對狂犬病疫苗的需求，並將其納入更廣泛的動物健康管理策略。此外，政府支持的舉措，特別是大規模疫苗接種運動，將在可預見的未來促進市場的成長。

狂犬病發生率的上升是主要的市場驅動力。世界動物衛生組織 (WOAH) 的數據突顯了狂犬病的嚴重性：每年約有 59,000 人因狂犬病死亡，其中 99% 是由狗咬傷造成的。這種病毒威脅主要針對哺乳動物，包括狗和貓等常見的家養寵物，症狀出現後死亡率幾乎達 100%。這些可怕的統計數據激發了全球對抗狂犬病的努力，最終導致了廣泛的疫苗接種活動。

全球獸用狂犬病疫苗產業根據動物類型、應用、最終用途、給藥途徑和地區進行分類。

市場依動物類型分為伴侶動物、牲畜和野生動物。伴侶細分市場進一步分為狗、貓等，2023 年的估值為2.646 億美元，引領市場。一需求。鑑於狗和貓是人類主要的狂犬病宿主，它們的疫苗接種對於公共衛生至關重要。此外，許多國家強制要求寵物接種狂犬病疫苗的法規凸顯了伴侶細分市場的市場主導地位。

從應用角度來看，市場分為暴露前預防和暴露後預防。 2023 年，暴露後細分市場佔據主導地位，佔 69.7% 的佔有率。獸用 PEP 疫苗在保護動物（尤其是寵物和牲畜）免受因與受感染實體接觸而感染狂犬病方面發揮著至關重要的作用。狂犬病症狀出現後幾乎肯定會死亡，這放大了市場上 PEP 的需求和重要性。

北美獸用狂犬病疫苗產業估值為1.976億美元。預測顯示，從 2024 年到 2032 年，複合年成長率為 3.8%。此外，主要製藥公司的存在及其積極的研發工作進一步加強了市場的主導地位。野生動物中狂犬病的高盛行率和強力的公共衛生舉措相結合，凸顯了北美對獸用狂犬病疫苗的需求，從而鞏固了該地區作為全球領導者的地位。

產業生態系統分析
產業影響力
- 成長動力
  - 狂犬病發生率上升
  - 全球寵物擁有量不斷增加
  - 有利的政府法規和政策
  - 提高對狂犬病及其預防的認知
- 產業陷阱與挑戰
  - 狂犬病疫苗成本高
  - 缺乏意識
成長潛力分析
監管環境
管道分析
波特的分析
PESTEL分析

第 4 章：競爭格局

介紹
公司矩陣分析
主要市場參與者的競爭分析
競爭定位矩陣
戰略儀表板

第 5 章：市場估計與預測：按動物類型，2021 - 2032

主要趨勢
伴侶動物
- 狗
- 貓
- 其他伴侶動物
畜牧動物
- 牛
- 綿羊和山羊
- 其他家畜動物
野生動物

第 6 章：市場估計與預測：按應用分類，2021 - 2032

主要趨勢
暴露前預防
暴露後預防

第 7 章：市場估計與預測：按管理途徑，2021 - 2032 年

主要趨勢
口服
可注射

第 8 章：市場估計與預測：按最終用途，2021 - 2032 年

主要趨勢
獸醫醫院和診所
動物收容所和救援組織
科學研究機構

第 9 章：市場估計與預測：按地區，2021 - 2032

主要趨勢
北美洲
- 美國
- 加拿大
歐洲
- 德國
- 英國
- 法國
- 西班牙
- 義大利
- 荷蘭
- 歐洲其他地區
亞太地區
- 日本
- 中國
- 印度
- 澳洲
- 韓國
- 亞太地區其他地區
拉丁美洲
- 巴西
- 墨西哥
- 拉丁美洲其他地區
中東和非洲
- 沙烏地阿拉伯
- 南非
- 阿拉伯聯合大公國
- 中東和非洲其他地區

第 10 章：公司簡介

Biogenesis Bago S.A.
Bioveta, a.s.
Boehringer Ingelheim International GmbH
Ceva Sante Animale S.A.
Dyntec
Elanco Animal Health Incorporated
Indian Immunologicals Limited
Merck and Co., Inc.
Vaxxinova International B.V.
Virbac S.A.
Zoetis Inc.

簡介目錄

Product Code: 10816

The Global Veterinary Rabies Vaccines Market was valued at USD 502.5 million in 2023 and is projected to grow at 4.2% CAGR from 2024 to 2032, attributed to the rising prevalence of rabies in animals and the growing awareness of its zoonotic implications.

The global surge in pet ownership has further propelled the market, as owners increasingly recognize the importance of vaccinating their pets against rabies. Urbanization and the growth of livestock farming in developing nations are also driving the demand for rabies vaccines, integrated into broader animal health management strategies. Additionally, government-backed initiatives, especially mass vaccination campaigns, are set to bolster the market's growth in the foreseeable future.

The rising incidence of rabies serves as a primary market driver. Data from the World Organization of Animal Health (WOAH) highlights the severity: rabies accounts for roughly 59,000 annual fatalities, with a staggering 99% stemming from dog bites. This viral menace predominantly targets mammals, including common domestic pets like dogs and cats, and boasts an almost 100% fatality rate post-symptom onset. Such dire statistics have galvanized global efforts to combat rabies, culminating in extensive vaccination drives.

The global veterinary rabies vaccines industry is classified based on animal type, application, end-use, route of administration and region.

The market categorizes based on animal type into companion animals, livestock, and wildlife. The companion segment, further divided into dogs, cats, and others, led the market with a valuation of USD 264.6 million in 2023. Heightened awareness among pet owners about rabies vaccination's significance, combined with a global uptick in pet ownership, has driven this demand. Given that dogs and cats are primary rabies reservoirs for humans, their vaccination becomes paramount for public health. Furthermore, many countries' regulations mandating pet rabies vaccinations underscore the companion segment's market dominance.

Application-wise, the market divides into pre-exposure and post-exposure prophylaxis. The post-exposure segment led with a commanding 69.7% share in 2023. Its dominance stems from its pivotal role in thwarting rabies onset after potential exposure. Veterinary PEP vaccines play a crucial role in protecting animals, especially pets and livestock, from rabies through contact with infected entities. The near-certain fatality of rabies post-symptom emergence amplifies the demand and significance of PEP in the market.

North America Veterinary Rabies Vaccines Industry was valued at USD 197.6 million. Projections indicate a growth at a CAGR of 3.8% from 2024 to 2032. The region is characterized by a strong veterinary healthcare infrastructure, an increase in awareness among pet owners, and strict government regulations that mandate rabies vaccinations for pets. Additionally, the market's dominance is further strengthened by the presence of major pharmaceutical companies and their active research and development efforts. The combination of a high prevalence of rabies in wildlife and strong public health initiatives highlights the demand for veterinary rabies vaccines in North America, reinforcing the region's position as a global leader.

Chapter 1 Methodology and Scope

1.1 Market scope and definitions
1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
1.3 Base estimates and calculations
- 1.3.1 Base year calculation
- 1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources

Chapter 2 Executive Summary

2.1 Industry 360° synopsis

Chapter 3 Industry Insights

3.1 Industry ecosystem analysis
3.2 Industry impact forces
- 3.2.1 Growth drivers
  - 3.2.1.1 Rising incidence of rabies
  - 3.2.1.2 Rising pet ownership globally
  - 3.2.1.3 Favorable government regulations and policies
  - 3.2.1.4 Increased awareness about rabies and its prevention
- 3.2.2 Industry pitfalls and challenges
  - 3.2.2.1 High cost of rabies vaccines
  - 3.2.2.2 Lack of awareness
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Pipeline analysis
3.6 Porter's analysis
3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

4.1 Introduction
4.2 Company matrix analysis
4.3 Competitive analysis of major market players
4.4 Competitive positioning matrix
4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Animal Type, 2021 - 2032 ($ Mn)

5.1 Key trends
5.2 Companion animals
- 5.2.1 Dogs
- 5.2.2 Cats
- 5.2.3 Other companion animals
5.3 Livestock animals
- 5.3.1 Cattle
- 5.3.2 Sheep and goats
- 5.3.3 Other livestock animals
5.4 Wildlife

Chapter 6 Market Estimates and Forecast, By Application, 2021 - 2032 ($ Mn)

6.1 Key trends
6.2 Pre exposure prophylaxis
6.3 Post exposure prophylaxis

Chapter 7 Market Estimates and Forecast, By Route of Administration, 2021 - 2032 ($ Mn)

7.1 Key trends
7.2 Oral
7.3 Injectable

Chapter 8 Market Estimates and Forecast, By End-use, 2021 - 2032 ($ Mn)

8.1 Key trends
8.2 Veterinary hospitals and clinics
8.3 Animal shelters and rescue organizations
8.4 Research institutes

Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

9.1 Key trends
9.2 North America
- 9.2.1 U.S.
- 9.2.2 Canada
9.3 Europe
- 9.3.1 Germany
- 9.3.2 UK
- 9.3.3 France
- 9.3.4 Spain
- 9.3.5 Italy
- 9.3.6 Netherlands
- 9.3.7 Rest of Europe
9.4 Asia Pacific
- 9.4.1 Japan
- 9.4.2 China
- 9.4.3 India
- 9.4.4 Australia
- 9.4.5 South Korea
- 9.4.6 Rest of Asia Pacific
9.5 Latin America
- 9.5.1 Brazil
- 9.5.2 Mexico
- 9.5.3 Rest of Latin America
9.6 Middle East and Africa
- 9.6.1 Saudi Arabia
- 9.6.2 South Africa
- 9.6.3 UAE
- 9.6.4 Rest of Middle East and Africa